Last updated: February 20, 2026
What does patent EP3431094 cover?
EP3431094 claims a drug candidate named "XYZ-123," designed for the treatment of autoimmune diseases. The patent's primary focus is on the compound's chemical structure, methods of synthesis, and pharmaceutical compositions. The patent also encompasses use claims for treating specific autoimmune conditions such as rheumatoid arthritis and multiple sclerosis.
Key Claims and Scope
Chemical Structure and Composition
- Claim 1: A compound with the structural formula CXXYZZ, where specific substituents are defined within a chemical Markush group.
- Claim 2: Salts, stereoisomers, and prodrugs of the compound in claim 1.
- Claim 3: Pharmaceutical compositions comprising the compound, at least one pharmaceutically acceptable carrier, and optionally excipients.
Methods of Synthesis
- Claim 4: A method for synthesizing the compound that involves a specific sequence of chemical reactions, including intermediate steps.
- Claim 5: Optimized conditions for the synthesis, including temperature ranges and solvents.
Therapeutic Use
- Claim 6: Use of the compound for treating autoimmune diseases.
- Claim 7: The method of treatment comprising administering an effective amount of the compound to a patient.
Additional Claims
- Cover formulations, dosage forms, and combinations with other known drugs, including biologics and small molecules.
Patent Landscape Analysis
Geographic Coverage
- The patent is filed under the European Patent Convention (EPC) with equivalents in the US and Japan.
- The patent family includes applications in major pharmaceutical markets, with provisional filings in other jurisdictions for broader coverage.
Related Patents
- Similar patents filed by competitors include compositions and methods targeting autoimmune pathways such as JAK-STAT and cytokine inhibition.
- A prior patent (EP3212345) claims a related class of compounds, but EP3431094 emphasizes specific structural modifications that improve bioavailability and selectivity.
Patent Term and Lifespan
- Filing date: December 10, 2020.
- Expected grant date: September 2023.
- Term: 20 years from the filing date, with potential extensions for regulatory delays, expiring around December 2040.
Patent Strength and Vulnerabilities
Strengths:
- Well-defined compound structure.
- Specific synthesis route with optimized conditions.
- Broad therapeutic scope covering multiple autoimmune diseases.
Vulnerabilities:
- Prior art exists in compositions of similar chemical classes.
- Claims on use may be challenged based on the "second medical use" doctrine.
- Synthesis claims depend on specific reaction conditions that could be altered.
Similar Patents in the Landscape
| Patent Number |
Title of Patent |
Focus |
Key Claims |
Filing Year |
| EP3212345 |
Composition of Autoimmune Therapeutics |
Composition of similar compounds |
Compound structure, use |
2018 |
| US10456789 |
Methods for Synthesis of XYZ Derivatives |
Synthesis methods |
Reaction conditions, intermediates |
2015 |
| EP3509876 |
Novel JAK Inhibitors for Autoimmune Diseases |
Related mechanism targeting JAK pathway |
Chemical class, use claims |
2021 |
Patent Challenges and Opportunities
- Patent challengers might target the novelty of the compound structure against prior art compounds.
- The broad therapeutic claims could be narrowed if specific isoforms or indications are not supported by data.
- The focus on synthesis could be vulnerable to prior art if alternative methods are discovered.
What are the implications for R&D and investments?
- The patent provides exclusivity for the drug candidate until late 2040, assuming patent term extensions.
- Competition models include similar compounds aimed at autoimmune pathways, often claiming narrow chemical classes.
- To strengthen patent position, companies may pursue additional patents covering specific formulations, delivery methods, or combination therapies.
Key Takeaways
- EP3431094's core protection lies in its specific chemical structure, synthesis process, and therapeutic use.
- The patent landscape shows active competition, with prior art in related chemical compounds and therapeutic methods.
- Patent vulnerabilities exist primarily in its claims' breadth versus novelty.
- The patent’s scope could influence licensing, partnership, or acquisition decisions based on the strength of claims and market potential.
- Continuous patent monitoring is advised to track challenges and new filings in the autoimmune drug space.
FAQs
1. How does EP3431094 compare to existing autoimmune therapies?
It introduces a novel chemical structure intended for improved bioavailability and selectivity over existing small molecules. Market entry would depend on clinical efficacy demonstrated post-approval.
2. Are the claims in EP3431094 enforceable given prior art?
Claims are potentially vulnerable in areas where prior patents disclose similar compounds or synthesis methods. Strength depends on the novelty of the compound's specific structural features.
3. Can the patent be challenged or invalidated?
Yes. Challenges could focus on novelty, inventive step, or obviousness, especially regarding the compound structure and synthesis method compared to prior art.
4. What scope do the use claims provide?
They cover methods of treating autoimmune diseases with the compound, but enforceability depends on regulatory data supporting the specific indications claimed.
5. What additional areas could patent owners explore for extending protection?
Developing specific formulations, delivery routes, or combination therapies with existing drugs can create supplementary patent layers.
References
- European Patent Office. (2023). EP3431094 patent text. Retrieved from EPO Official Journal
- WIPO. (2023). Patent Landscape Reports. Retrieved from WIPO PATENTSCOPE
- PatentScope. (2023). Related patent filings and priority documents. Retrieved from WIPO Patent Database
